Discussion
We present here a patient with sarcoidosis limited to the stomach and complicated by pernicious anaemia who was treated conservatively with oral corticosteroids. The stomach is a rare site of sarcoid involvement. A review by Maycock et al. reported no cases of gastric involvement among 1109 patients'. In 1979 Korsager reported a case of gastric and pulmonary sarcoidosis and identified an additional 45 cases in the literature of sarcoidosis with gastric involvement2. Several subsequent cases have been reported of patients with sarcoidosis involving the stomach as well as other organs5-11. In only one of these cases5, a 22-year-old woman with sarcoidosis ofthe thyroid, lungs, phalanges, oesophagus, stomach, duodenum, appendix and lungs, did the individual have concomitant pernicious anaemia. A second case6 has been reported of sarcoidosis of the liver, spleen, lungs, stomach, small intestine, colon and rectum in a 60-year-old woman who had an abnormal Schilling test both with and without intrinsic factor in the setting of mild generalized malabsorption but no reported resultant anaemia.
Chlumsky et al.3 reported a case of a 31-year-old man with isolated gastric sarcoidosis which responded to oral corticosteroid therapy. Gallagher et aL4 presented two cases of gastric sarcoidosis, one with concomitant pulmonary involvement and the other being a 25-year-old woman with isolated gastric sarcoidosis discovered at laparotomy; no further treatment beyond resection was needed. Berens and Montes'2 also presented two cases of gastric sarcoidosis, one with concomitant pulmonary and liver involvement and the other being a 35-year-old woman with presumed isolated gastric involvement, although in this case the evaluation was incomplete. Fahimi and his colleagues"3 reported three additional cases of patients with isolated granulomatous gastritis; however, they were unconvinced that these were sarcoidosis.
Thus, review ofthe literature confirms the rarity of gastric involvement in sarcoidosis. Furthermore, isolated gastric sarcoidosis appears to be extremely rare with only six prior potential cases reported in the world literature, and in some of these the diagnosis was questionable. Finally, there is only one prior report in the world literature of gastric sarcoidosis leading to pernicious anaemia. Therefore, we feel that our patient represents a highly unusual presentation of sarcoidosis with isolated gastric involvement and concomitant pernicious anaemia. A syndrome of disabling fatigue variously labelled myalgic encephalomyelitis (ME), post-viral fatigue, or chronic fatigue syndrome (CFS)1 has received much recent attention23. Depression occurs in up to half of hospital referrals with CFS4-f and in these cases, may explain the symptoms7. However, despite suggestions of muscular dysfunction8 the cause in the remainder is unknown. The following case is reported with reference to this question.
Case report A 17-year-old schoolgirl was admitted with mania. Three years earlier, she had suffered recurrent episodes of fatigue, increased sleep, poor concentration, muscle pains and sore throat, each lasting several days. Post-viral fatigue syndrome was diagnosed. Physical examination and investigations were negative. Psychiatric assessment excluded depressive disorder. Review of the case notes confirms that the patient met criteria for CFS1. One year later she took an impulsive overdose. Psychiatric assessment again excluded depressive disorder as did a further assessment by a third psychiatrist 6 months later.
Since the onset of illness she had become profoundly disabled, had stopped attending school, and was house-bound. Ten days prior to admission her general practitioner had prescribed a trial of amitriptyline 150 mg.
The patient's family history, personal development before the onset of illness and past medical history were unremarkable. Her pre-morbid personality was reported as cheerful, energetic and popular with friends. The patient and her family believed that the illness was ME, that aches after exercise indicated relapse, and that rest was the best treatment.
Physical examination and investigations on admission (full blood count and erythrocyte sedimentation rate, biochemistry, serum tri-iodothyronine) were all within the normal range. Epstein-Barr virus IgM and monospot test were negative but IgG positive (1/50) suggesting previous In hospital she was treated with droperidol and procyclidine. Whilst manic she was overactive, and slept little. She denied fatigue. Four weeks later when euthymic she could still perform activities not attempted for more than a year. These included long walks, cycling, and badminton, none of which now caused her pain or undue fatigue. She remained well over the following month, medication was discontinued, and she returned home.
This case illustrates recovery of CFS following mania. Why did she recover? Could the coincidence of mania and recovery have been due to chance? We think that this is unlikely given the chronicity of her condition. Could the antidepressant have been a common factor causing both mania and recovery? Antidepressants can probably trigger mania'°.
There is also anecdotal evidence that they can reduce disability in CFS, and good evidence in a similar condition called fibromyalgia". However, we consider it more likely that elevation of mood caused her recovery. Increased energy and immunity to fatigue have long been observed during mania'2, but the persistence of recovery suggests a more permanent change in factors maintaining her disability.
Depression is one possible factor. This possibility is supported by the history of overdose, intermittent low mood and impaired energy and concentration. Furthermore, the development of mania suggests a bipolar predisposition. Against are the negative psychiatric assessments. The case for a primary depressive disorder is therefore unproven and presupposes an atypical or 'masked' presentation.
Psychosocial factors'3 may also maintain disability. A belief that (benign) activity associated symptoms indicate damage may lead to avoidance of activity and hence to disability'4. Family members may reinforce both beliefs and avoidance. There is evidence that similar fears can be reduced by elevation of mood".
We suggest that the clinical assessment of patients presenting with CFS should consider not only physical pathology, but also mood, beliefs, avoidance of activity, and the role of the family. To develop and market a new chemical entity (NCE) can now take 10-12 years and cost £100 million or more. On 19 March 1990, representatives of the pharmaceutical industry, the UK regulatory authority and Government met at the Royal Society of Medicine to discuss the difficulties encountered in new drug development at all levels and to recommend possible solutions.
The morning session, entitled 'How is industry improving its development process?', was chaired by Dr David Jack (ex-Chairman and Chief Executive, Glaxo Group Research).
Thinking strategically
As the first speaker, Dr Tony Kennedy (Project Director, SmithKline Beecham) pointed out that strategic reappraisal of projects as they move forward from research to development and during development itself is essential to ensure that the talents and resources of a company are concentrated upon projects of real value. He emphasized the importance of the product profile, which defines the expectations for a new product in terms of its efficacy, safety, dosing regimen, presentation and labelling and can be used as a strategic tool to assess the impact of development findings and external events upon the commercial opportunity. 'Gold' standards of therapy frequently change during the development of an NCE rendering an earlier target product profile obsolete; the use of HMG CoA reductase inhibitors in the treatment of hypercholesterolaemia and ACE inhibitors in congestive heart failure were quoted as examples. Equally, information derived from studies of clinical efficacy and safety or long term toxicology may result in a reappraisal of the medical and commercial opportunity for a drugperhaps leading to termination of the project. The failure of the majority of NCEs to repay their development costs would seem to indicate that such painful decisions are frequently not taken. 
